alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 520.823 Erythromycin. ( a ) *Specifications.* Each gram of powder contains erythromycin phosphate equivalent to 0.89 gram of erythromycin master standard.
( b ) *Sponsor.* See No. 061133 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.230 of this chapter.
( d ) *Conditions of use.* It is used in drinking water as follows: ( 1 ) *Broiler and replacement chickens* — ( i ) *Amount.* Administer 0.500 gram per gallon for 5 days.
( ii ) *Indications for use.* As an aid in the control of chronic respiratory disease due to *Mycoplasma gallisepticum* susceptible to erythromycin.
( iii ) *Limitations.* Do not use in replacement pullets over 16 weeks of age. Do not use in chickens producing eggs for human consumption. Withdraw 1 day before slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Replacement chickens and chicken breeders* — ( i ) *Amount.* Administer 0.500 gram per gallon for 7 days.
( ii ) *Indications for use.* As an aid in the control of infectious coryza due to *Haemophilus gallinarum* susceptible to erythromycin.
( iii ) *Limitations.* Do not use in replacement pullets over 16 weeks of age. Do not use in chickens producing eggs for human consumption. Withdraw 1 day before slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 3 ) *Growing turkeys* — ( i ) *Amount.* Administer 0.500 gram per gallon for 7 days.
( ii ) *Indications for use.* As an aid in the control of blue comb (nonspecific infectious enteritis) caused by organisms susceptible to erythromycin.
( iii ) *Limitations.* Do not use in turkeys producing eggs for human consumption. Withdraw 1 day before slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 45 FR 56798, Aug. 26, 1980; 66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 2003; 79 FR 28821, May 20, 2014; 81 FR 17607, Mar. 30, 2016; 81 FR 94989, Dec. 27, 2016; 84 FR 8972, Mar. 13, 2019]
38854.

#### LEVINE v. SELEY.

Eberhardt, Judge.

The Supreme Court of Georgia having reversed the judgment of this court in the above matter *(Levine*
      *775
      *v. Seley,*217 Ga. 384, 123 SE2d 1), the opinion and judgment of this court heretofore rendered on May 19, 1961 *(Levine v. Seley,*103 Ga. App. 781, 120 SE2d 676) is hereby vacated and set aside. In conformity with the judgment of the Supreme Court the judgment of the trial court is hereby affirmed on condition that the amount thereof be written down to sums agreed and stipulated by the parties in a written stipulation dated February 22, 1961 and filed in the cause, not to have been barred by the statute of limitation and thus to have been due; otherwise it is reversed. In any event it is ordered and directed that the costs on appeal be taxed against the defendant in error.

Decided November 10, 1961.

*Candler, Cox, McClain & Andrews, Edward Andrews,*for plaintiff in error.

*Sidney Haskins,*contra.

*Judgment affirmed on condition.*

*Carlisle, P. J., and Nichols, J., concur.*
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 9016]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3939]


-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration


Fifty-Fifth Meeting, RTCA Special Committee 135: Environmental 
Conditions and Test Procedures for Airborne Equipment

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of RTCA Special Committee 135: Environmental Conditions 
and Test Procedures for Airborne Equipment meeting.

-----------------------------------------------------------------------

SUMMARY: The FAA is issuing this notice to advise the public of a 
meeting of RTCA Special Committee 135: Environmental Conditions and 
Test Procedures for Airborne Equipment.

DATES: The meeting will be held March 17-19, 2010, starting at 9 a.m.

ADDRESSES: The meeting will be held at Honeywell International Inc., 
Deer Valley Facilities, 21111 N. 19th Ave., Phoenix, AZ.

FOR FURTHER INFORMATION CONTACT: (1) RTCA Secretariat, 1828 L Street, 
NW., Suite 805, Washington, DC 20036; telephone (202) 833-9339; fax 
(202) 833-9434; Web site http://www.rtca.org.

SUPPLEMENTARY INFORMATION: Pursuant to section 10(a)(2) of the Federal 
Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., Appendix 2), notice 
is hereby given for a Special Committee 135: Environmental Conditions 
and Test Procedures for Airborne Equipment meeting. The agenda will 
include:

October 28-30

<bullet> Opening Session (Welcome, Chairman's Opening Remarks, 
Introductions)
<bullet> Approval of Summary from the Fifty-Fourth Meeting.
<bullet> RTCA Paper No. 006-10/SC135-676
<bullet> Status and Review of Revision of AC
<bullet> Report from Section 16, 20, 21, & 26 Working Groups
<bullet> Review List of Change Proposals for DO-160G/ED-14G
<bullet> Status of User Guide Material
<bullet> Review Schedule for DO-160G
<bullet> New/Unfinished Business
<bullet> Establish Date for Next SC-135 Meeting
<bullet> Closing

    Attendance is open to the interested public but limited to space 
availability. With the approval of the chairmen, members of the public 
may present oral statements at the meeting. Persons wishing to present 
statements or obtain information should contact the person listed in 
the ``FOR FURTHER INFORMATION CONTACT'' section. Members of the public 
may present a written statement to the committee at any time.

    Issued in Washington, DC, on February 19, 2010.
Francisco Estrada C.,
RTCA Advisory Committee.
[FR Doc. 2010-3939 Filed 2-25-10; 8:45 am]
BILLING CODE 4910-13-P
#### § 1.1200 Are the records obtained by FDA under this subpart subject to public disclosure?

Records obtained by FDA under this subpart are subject to the disclosure requirements under part 20 of this chapter.
<PAGE>   1
                                                                   EXHIBIT 10.44


                      [UNION BANK OF CALIFORNIA LETTERHEAD]

                                      Date
                                January 26, 1998



John Hohener, CFO
SMARTFLEX SYSTEMS INCORPORATED
14312 Franklin Avenue
Tustin, CA  92781-2085

               NOTICE OF WAIVER
               Re:  Loan Agreement
               Dated:  September 26, 1997

Dear Mr. Hohener:

        You have requested the following waiver(s) in reference to the Loan
Agreement ("Agreement") between Union Bank of California, N.A. ("Bank") and
Smartflex Systems Incorporated ("Borrower") referred to above.

        Bank hereby waives Borrower's breach of Section 4.8 Profit From
Operations and Section 4.9 Cash Flow of the Agreement occurring prior to January
1, 1998. Any further breach of these sections is not waived.

        Except as waived hereby, the Agreement, as the same may have previously
been waived, shall remain unaltered and in full force and effect. This letter
shall not be a waiver of any existing default or breach of a covenant unless
specified herein.

        If you agree with the foregoing, please sign the enclosed
acknowledgement copy and return it on or before February 15, 1998.

                                            UNION BANK OF CALIFORNIA, N.A.


                                            By      Robert Thomas
                                                    ----------------------------
                                            Title:  Vice President
                                                    ----------------------------


                                            By      Jack Penhoff
                                                    ----------------------------
                                            Title:  Vice President
                                                    ----------------------------




<PAGE>   2

SMARTFLEX SYSTEMS INCORPORATED hereby agree to and 
acknowledge this waiver this 30 day of January, 1998.


By      //s// John Hohener
        ----------------------------
Title:  VP/CFO
        ----------------------------



By
        ----------------------------
Title
        ----------------------------
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    By Notice dated October 16, 2009, and published in the                     **Federal Register**                     on October 28, 2009 (74 FR 55584), Clinical Supplies Management, 342 42nd Street South, Fargo, North Dakota 58103, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Poppy Straw Concentrate (9670), a basic class of controlled substance listed in schedule II.                

The company plans to import an ointment for the treatment of wounds which contains trace amounts of controlled substances normally found in poppy straw concentrate which will be packaged and labeled for clinical trials.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a), and determined that the registration of Clinical Supplies Management to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Clinical Supplies Management to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: February 24, 2010.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2010-4439 Filed 3-2-10; 8:45 am]

BILLING CODE 4410-09-P
<TABLE>
<CAPTION>

                                                               Exhibit 21.1


                      Subsidiaries as of December 31, 1999
                      ------------------------------------


         Name                      Jurisdiction of Incorporation     Percent Ownership
         ----                      -----------------------------     -----------------
<S>                                <C>                                   <C>
Golfweb                            California                            100%
Sports.com                         United Kingdom                        54.61%
Commissioner.com, Inc.             Delaware                              100%
International Golf Outlet, Inc.    Texas                                 100%
Golf Club Trader, Inc.             Texas                                 100%
Tennis Direct.com, Inc.            Delaware                              100%



</TABLE>
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1991 Zinc oxide. ( a ) *Identity.* ( 1 ) The color additive zinc oxide is a white or yellow-white amorphous powder manufactured by the French process (described as the indirect process whereby zinc metal isolated from the zinc-containing ore is vaporized and then oxidized). It is principally composed of Zn.
( 2 ) Color additive mixtures for drug use made with zinc oxide may contain only those diluents listed in this subpart as safe and suitable in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* Zinc oxide shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Zinc oxide (as ZnO), not less than 99 percent. Loss on ignition at 800 °C, not more than 1 percent. Cadmium (as Cd), not more than 15 parts per million. Mercury (as Hg), not more than 1 part per million. Arsenic (as As), not more than 3 parts per million. Lead (as Pb), not more than 20 parts per million.
( c ) *Uses and restrictions.* The color additive zinc oxide may be safely used for coloring externally applied drugs, including those used in the area of the eye, in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The color additive and any mixtues prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any information required by law, labeling in accordance with the provisions of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches therof are exempt from the certifiation pursuant to section 721(c) of the act.
[42 FR 37537, July 22, 1977]
Exhibit 32
 Certification of Periodic Financial Report
 Pursuant to 18 U.S.C. Section 1350
   Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of AMCOL International Corporation (the “Company”) certifies that the quarterly report on Form 10-Q of the Company for the nine months ended September 30, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 Date:  November 2, 2010
/s/ Lawrence E. WashowLawrence E. Washow

Chief Executive OfficerDate:  November 2, 2010
/s/ Donald W. PearsonDonald W. Pearson

Chief Financial Officer
§ 74.1261 D&C Orange No. 11. ( a ) *Identity.* ( 1 ) The color additive D&C Orange No. 11 is a mixture consisting principally of the disodium salts of 4′,5′-diiodofluorescein, 2′,4′,5′-triiodofluorescein and 2′,4′,5′,7′-tetraiodofluorescein.
( 2 ) Color additive mixtures for drug use made with D&C Orange No. 11 may contain only those diluents listed in this subpart as safe and suitable for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* The color additive D&C Orange No. 11 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Sum of volatile matter (at 135 °C) and halides and sulfates (calculated as sodium salts), not more than 8 percent. Water-insoluble matter, not more than 0.5 percent. Phthalic acid, not more than 0.5 percent. 2-[3′,5′-Diiodo-2′,4′-dihydroxybenzoyl] benzoic acid, sodium salt, not more than 0.5 percent. Fluorescein, disodium salt, not more than 1 percent. 4′-Iodofluorescein, disodium salt, not more than 3 percent. 2′,4′-Diiodofluorescein and 2′,5′-diiodofluorescein, not more than 2 percent. 2′,4′,5′-Triiodofluorescein, not more than 35 percent. 2′,4′,5′,7′-Tetraiodofluorescein, disodium salt, not more than 10 percent. 4′,5′-Diiodofluorescein, disodium salt, not less than 60 percent and not more than 95 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 92 percent.
( c ) *Uses and restrictions.* D&C Orange No. 11 may be safely used for coloring externally applied drugs in amounts consistent with good manufacturing practice.
( d ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Orange No. 11 shall be certified in accordance with regulations in part 80 of this chapter.
[46 FR 18953, Mar. 27, 1981]
Exhibit 99 - Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code
 

      I, Shaun  O'Brien,  the Chief  Financial  Officer of CIS  Investments,  Inc.  ("CISI"),  the General Partner ofIDS Managed Futures II, L.P.(the "Partnership"),  and I, James A.  Davison,  the  President of CISI,  certify that (i) the attached  10-Q fullycomplies with the  requirements  of Section 13(a) or 15(d) of the Securities  Exchange Act of 1934 and (ii) the informationcontained in the attached Form 10-Q fairly  presents,  in all material  respects,  the  financial  condition and results ofoperations of the Partnership.
 

 
James A. Davison         President         CIS Investments, Inc.         August 13, 2003 Shaun D. O'Brien         Chief Financial Officer         CIS Investments, Inc.         August 13, 2003
§ 582.1480 Methylcellulose. ( a ) *Product.* U.S.P. methylcellulose, except that the methoxy content shall not be less than 27.5 percent and not more than 31.5 percent on a dry-weight basis.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 530.22 Safe levels and analytical methods for food-producing animals. ( a ) FDA may establish a safe level for extralabel use of an approved human drug or an approved new animal drug when the agency finds that there is a reasonable probability that an extralabel use may present a risk to the public health. FDA may: ( 1 ) Establish a finite safe level based on residue and metabolism information from available sources;
( 2 ) Establish a safe level based on the lowest level that can be measured by a practical analytical method; or
( 3 ) Establish a safe level based on other appropriate scientific, technical, or regulatory criteria.
( b ) FDA may require the development of an acceptable analytical method for the quantification of residues above any safe level established under this part. If FDA requires the development of such an acceptable analytical method, the agency will publish notice of that requirement in the Federal Register.
( c ) The extralabel use of an animal drug or human drug that results in residues exceeding a safe level established under this part is an unsafe use of such drug.
( d ) If the agency establishes a safe level for a particular species or category of animals and a tolerance or safe concentration is later established through an approval for that particular species or category of animals, for that species or category of animals, the safe level is superseded by the tolerance or safe concentration for that species or category of animals.
# C_2015073EN.01000902.xml

| 2.3.2015 | EN | Official Journal of the European Union | C 73/9 |
| --- | --- | --- | --- |

2.3.2015

EN

Official Journal of the European Union

C 73/9

---

Request for a preliminary ruling from the Amtsgericht Rüsselsheim (Germany) lodged on 10 October 2014 — Dieter Wedzel, Karin Wedzel v Condor Flugdienst GmbH

(Case C-466/14)

(2015/C 073/13)

Language of the case: German

Referring court

Amtsgericht Rüsselsheim

Parties to the main proceedings

Applicants: Dieter Wedzel, Karin Wedzel

Defendant: Condor Flugdienst GmbH

The case was removed from the Register of the Court of Justice by order of the Court of 9 December 2014.

---
# C_2015081EN.01000202.xml

| 9.3.2015 | EN | Official Journal of the European Union | C 81/2 |
| --- | --- | --- | --- |

9.3.2015

EN

Official Journal of the European Union

C 81/2

---

Request for a preliminary ruling from the Wojewódzki Sąd Administracyjny w Szczecinie (Poland) lodged on 1 July 2014 — ASPROD sp. z o.o. v Dyrektor Izby Celnej w Szczecinie

(Case C-313/14)

(2015/C 081/03)

Language of the case: Polish

Referring court

Referring court

Wojewódzki Sąd Administracyjny w Szczecinie

Parties to the main proceedings

Parties to the main proceedings

Applicant: ASPROD sp. z o.o.

Applicant:

Defendant: Dyrektor Izby Celnej w Szczecinie

Defendant:

By order of 3 December 2014, the Court of Justice (Second Chamber) ruled that Article 27(1)(f) of Council Directive 92/83/EEC of 19 October 1992 on the harmonisation of the structures of excise duties on alcohol and alcoholic beverages (1) must be interpreted as precluding national rules, such as those at issue in the main proceedings, which make the application of the exemption from the harmonised excise duty provided for under that provision subject to the condition that the trader concerned must hold a decision from the tax administration fixing the maximum limits for use of the products exempted under that provision.

1

---

(1)  OJ 1992 L 316, p. 21.

1

---